Preview Of Corcept Therapeutics Incorporated ($CORT) 2Q20 Earnings

93

Corcept Therapeutics Incorporated (NASDAQ:CORT) bio-pharma drug manufacturer, is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020.

Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.22 per share.

Looking ahead, the full year income are expected at $ 0.89 per share on the revenues of $ 368.27 million.

The Company Outlook

Full Year 2020 topline are forecasted in a range of$ 355.00 million ~ $ 375.00 million

Click Here For More Historical Outlooks Of Corcept Therapeutics Incorporated

Previous Quarter Performance

Corcept Therapeutics Incorporated came out with income for the first quarter of $ 0.34 per share, from the revenue of $ 93.25 million. The quarterly earnings swell 126.67 percent compared with the same quarter last year. Wall street analysts are predicting, CORT to report 1Q20 income of $ 0.22 per share from revenue of $ 87.01 million. The bottom line results beat street analysts by $ 0.12 or 54.55 percent, at the same time, top line results outshined analysts by $ 6.24 million or 7.17 percent.

Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!

Click Here For More Historical Earnings Of Corcept Therapeutics Incorporated

Stock Performance

According to the previous trading day, closing price of CORT was $ 15.35, representing a 58.25 % increase from the 52 week low of $ 9.70 and a 17.12 % decrease over the 52 week high of $ 18.52.

The company has a market capital of $ 1.76 billion and is part of the Healthcare sector and Biotechnology industry.

[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CORT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]

Conference Call

Corcept Therapeutics Incorporated will be hosting a conference call at 5:00 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.corcept.com

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushings syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors.